Positive OS Data for Atebimetinib (IMM-1-104) from Ph 2a Trial in 1L Pancreatic Cancer Patients Reported June 24, 2025
IDeate-Prostate01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic CRPC June 24, 2025
Zanzalintinib + Tecentriq Combination Improved OS in STELLAR-303 Ph 3 Pivotal Trial in Patients with Metastatic CRC June 24, 2025
FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations June 24, 2025
FDA grants Orphan Drug Designation to ADoBind MC001 for the treatment of pancreatic cancer June 24, 2025
Orion and Glykos announce the extension of research collaboration and licensing agreement for the development of next-gen ADCs June 24, 2025
Marker Therapeutics and Cellipont Bioservices to Advance cGMP Manufacturing of MT-601 for Patients with Lymphoma June 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel ADC Targeting CDH6 June 24, 2025
Enterome raises $19M to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma June 24, 2025
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies June 24, 2025
Recruitment for [212Pb]VMT-α-NET Commenced in the Third Dose Escalation Cohort of Ongoing Ph 1/2a Clinical Trial June 24, 2025
First Patient Completes DLT Observation Period with No Reported DLTs in Ph 1 Trial of CER-1236 June 24, 2025
Positive Biomarker and Machine Learning Data from Ph 2 Elraglusib Trial in 1L Treatment of Metastatic Pancreatic Cancer Announced June 24, 2025
Positive Interim Firmonertinib Monotherapy Data Announced From Global Ph 1b Study in EGFR PACC Mutant NSCLC; Plans to Advance into a Global Pivotal Study June 24, 2025
First Data from MZL Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) Presented June 24, 2025
Positive Ph 2 interim results in R/R indolent NHL after EO2463 OncoMimics immunotherapy treatment presented June 24, 2025
Positive New Clinical Data Demonstrating High Rates of Durable CRs from the Ph 1/2 Trial of LYL314 in Aggressive Large B-cell Lymphoma Announced June 24, 2025
Lunsumio and Polivy Combination Significantly Prolongs Remission for People With R/R Large B-Cell Lymphoma June 24, 2025
Breakthrough Therapy Designation application for oral gallium maltolate (GaM) in refractory brain tumors voluntarily withdrawn and resubmitted June 24, 2025
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma June 24, 2025
